PRECISION BIOSCIENCES INC - Common Stock, $0.000005 par value per share (DTIL)
CUSIP: 74019P207
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Stock, $0.000005 par value per share
- Shares outstanding
- 25,804,443
- Total 13F shares
- 3,442,623
- Share change
- +123,075
- Total reported value
- $18,934,427
- Price per share
- $5.50
- Number of holders
- 14
- Value change
- +$676,914
- Number of buys
- 6
- Number of sells
- 2
Quarterly Holders Quick Answers
What is CUSIP 74019P207?
CUSIP 74019P207 identifies DTIL - PRECISION BIOSCIENCES INC - Common Stock, $0.000005 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Previous quarter: Q4 2025
Recent filing periods for CUSIP 74019P207:
Top shareholders of DTIL - PRECISION BIOSCIENCES INC - Common Stock, $0.000005 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Empery Asset Management, LP |
13D/G
13F
|
Company |
7.6%
|
1,968,879
|
$10,828,834 | -$1,808,961 | 31 Mar 2026 | |
| Octagon Capital Advisors LP |
13D/G
13F
|
Company |
10%
|
2,328,485
|
$9,570,073 | $0 | 31 Dec 2025 | |
| Aberdeen Group plc |
13D/G
13F
|
Company |
8.9%
|
2,138,603
|
$8,896,588 | $0 | 31 Dec 2025 | |
| Bleichroeder LP |
13D/G
13F
|
Company |
8.2%
|
1,900,000
|
$7,809,000 | +$3,390,750 | 31 Dec 2025 | |
| Readout Capital, LP |
13D/G
|
Matthew Smith |
9.4%
|
1,119,311
|
$4,980,934 | +$829,645 | 30 Jun 2025 | |
| NOVARTIS PHARMA AG |
3/4/5
13D/G
|
10%+ Owner |
3.7%
from 13D/G
|
12,407,440
|
$4,590,753 | — | 15 Jun 2022 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
4.1%
|
1,066,050
|
$4,434,768 | — | 31 Dec 2025 | |
| Lynx1 Capital Management LP |
13F
13D/G
|
Company |
4.1%
from 13D/G
|
993,913
|
$4,134,678 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.5%
|
906,782
|
$3,772,213 | — | 31 Dec 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
3.1%
|
798,000
|
$3,319,680 | — | 31 Dec 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
3.1%
|
787,700
|
$3,276,832 | — | 31 Dec 2025 | |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC |
13D/G
|
— |
3.7%
|
406,250
|
$2,165,312 | $0 | 31 Mar 2025 | |
| Weinstein Benjamin |
13D/G
|
— |
5.2%
|
395,489
|
$2,107,956 | $0 | 18 Mar 2025 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
1.5%
|
396,116
|
$1,647,843 | — | 31 Dec 2025 | |
| Derek Jantz |
3/4/5
|
Chief Scientific Officer, Director |
—
mixed-class rows
|
4,079,565
mixed-class rows
|
$1,509,439 | — | 07 Jun 2022 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.3%
|
326,477
|
$1,358,144 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.87%
|
225,657
|
$938,763 | — | 31 Dec 2025 | |
| Michael Amoroso |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
378,985
mixed-class rows
|
$934,625 | -$246,183 | 17 Feb 2026 | |
| Matthew R. Kane |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
2,026,513
mixed-class rows
|
$749,324 | — | 07 Jun 2021 | |
| BlackRock, Inc. |
13F
|
Company |
0.65%
|
168,331
|
$700,256 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.54%
|
139,531
|
$580,449 | — | 31 Dec 2025 | |
| J. Jefferson Smith |
3/4/5
|
Chief Research Officer |
—
mixed-class rows
|
163,190
mixed-class rows
|
$500,236 | -$60,018 | 17 Feb 2026 | |
| John Alexander Kelly |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
181,049
mixed-class rows
|
$483,390 | -$164,220 | 17 Feb 2026 | |
| MORGAN STANLEY |
13F
|
Company |
0.39%
|
99,805
|
$415,189 | — | 31 Dec 2025 | |
| 683 Capital Management, LLC |
13F
|
Company |
0.38%
|
97,085
|
$403,874 | — | 31 Dec 2025 | |
| COMMONWEALTH EQUITY SERVICES, LLC |
13F
|
Company |
0.36%
|
93,306
|
$388,150 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.34%
|
86,464
|
$359,690 | — | 31 Dec 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.32%
|
83,443
|
$347,123 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.27%
|
70,915
|
$295,004 | — | 31 Dec 2025 | |
| Quarry LP |
13F
|
Company |
0.26%
|
68,311
|
$284,174 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.26%
|
66,581
|
$276,977 | — | 31 Dec 2025 | |
| Quadrature Capital Ltd |
13F
|
Company |
0.24%
|
62,129
|
$258,457 | — | 31 Dec 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.24%
|
61,901
|
$257,508 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.24%
|
61,332
|
$255,141 | — | 31 Dec 2025 | |
| OMERS ADMINISTRATION Corp |
13F
|
Company |
0.24%
|
60,700
|
$252,512 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.23%
|
59,042
|
$245,615 | — | 31 Dec 2025 | |
| Kevin Buehler |
3/4/5
|
Director |
—
mixed-class rows
|
49,137
mixed-class rows
|
$234,961 | +$21,116 | 25 Jun 2025 | |
| Melinda Brown |
3/4/5
|
Director |
—
mixed-class rows
|
44,346
mixed-class rows
|
$233,941 | +$20,673 | 15 Dec 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.22%
|
56,315
|
$233,000 | — | 31 Dec 2025 | |
| Geno J. Germano |
3/4/5
|
Director |
—
mixed-class rows
|
44,883
mixed-class rows
|
$230,639 | +$14,160 | 16 Dec 2025 | |
| Dario Scimeca |
3/4/5
|
General Counsel and Secretary |
—
mixed-class rows
|
89,790
mixed-class rows
|
$216,794 | -$58,909 | 17 Feb 2026 | |
| Stanley R. Frankel |
3/4/5
|
Director |
—
mixed-class rows
|
40,478
mixed-class rows
|
$209,458 | +$26,109 | 16 Dec 2025 | |
| Shari Lisa Pire |
3/4/5
|
Director |
—
mixed-class rows
|
35,028
mixed-class rows
|
$189,875 | — | 27 May 2025 | |
| Trexquant Investment LP |
13F
|
Company |
0.16%
|
40,256
|
$167,465 | — | 31 Dec 2025 | |
| Samuel C. Wadsworth |
3/4/5
|
Director |
—
mixed-class rows
|
14,028
mixed-class rows
|
$161,277 | — | 04 Jun 2024 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.15%
|
38,767
|
$161,000 | — | 31 Dec 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.14%
|
35,929
|
$149,465 | — | 31 Dec 2025 | |
| Jump Financial, LLC |
13F
|
Company |
0.14%
|
35,790
|
$148,886 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.11%
|
29,607
|
$123,165 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.09%
|
23,757
|
$98,829 | — | 31 Dec 2025 |
Institutional Holders of PRECISION BIOSCIENCES INC - Common Stock, $0.000005 par value per share (DTIL) as of Q1 2026
As of 31 Mar 2026,
PRECISION BIOSCIENCES INC - Common Stock, $0.000005 par value per share (DTIL) was held by
14 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,442,623 shares.
The largest 10 holders included
Aberdeen Group plc, Lynx1 Capital Management LP, COMMONWEALTH EQUITY SERVICES, LLC, UBS Group AG, Miller Financial Services LLC, LPL Financial LLC, NFSG Corp, CrossGen Wealth, LLC, SBI Securities Co., Ltd., and Beacon Financial Strategies CORP.
This page lists
14
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
67
Q1 2026 holders
14
Holder diff
-53
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.